Frutarom Switzerland Ltd.
Bursting with polyphenols, Pink Rock Rose Extract EFLA®717, produced according to GMP and ISO guidelines, offers new opportunities in the market for respiratory affections.
With EFLA 717 Pink Rock Rose Extract, Frutarom has launched the most recent natural health protection product for the respiratory system, the gastrointestinal tract, as well as the skin. The extract is manufactured from Pink Rock Rose (Cistus incanus L.), one of the plants with the highest polyphenol content worldwide, and enhances the body's own cellular protective mechanisms in its combat against environmental burden such as bacteria, viruses or pollutants.
The active ingredients profile of EFLA 717 Pink Rock Rose Extract is rich in polyphenolic compounds such as flavonols, proanthocyanidins and flavan-3-ols. This is also reflected in the quadruple characterization of the extract on polyphenoles, myricetin, quercetin and kaempferol.
Thanks to its spectrum of ingredients, EFLA 717 Pink Rock Rose Extract helps prevent and treat infectious and inflammatory respiratory diseases such as catarrh, bronchitis and common cold. To date, echinacea has dominated this market and enjoyed growing potential. Moreover, EFLA 717 Pink Rock Rose Extract is supportive in treating heartburn, spasms and diarrhea. It mediates a gastroprotective effect and is beneficial in treating acne and neurodermitis.
As a monocompound or in combination with minerals, vitamins or other herbal extracts; and as a form of natural health protection, EFLA 717 Pink Rock Rose Extract offers manufacturers of phytopharmaceutics, dietary supplements and functional foods the possibility to enrich their product range with a new, premium extract in the target markets infection prophylaxis as well as gastrointestinal and skin health.
Access Food Processing and Wellness Foods magazines on-line and receive an e-mail each month when your new issue is ready. Subscribe Now »
Biweekly updates delivering feature articles, top industry news, company news, product announcements, technical issues and more. Subscribe Now »